Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioExx Receives Final Scale-Up Engineering Report

Published: Thursday, August 02, 2012
Last Updated: Thursday, August 02, 2012
Bookmark and Share
Company announced that it has received the report from GEA Process Engineering Inc. for the Company's Saskatoon canola protein facility.

The report, which details the complete protein system and equipment requirements to operate at full scale, as well as layouts and project schedules, is based on months of rigorous pilot testing of key unit operations throughout the plant. Capital cost estimates have not changed materially from the preliminary report, and the range has been tightened to provide greater certainty. This intensive study was completed in three phases, inclusive of production capacity for the Company's Isolexx(R) and Vitalexx(R) products, and further reinforces the technical and economic feasibility of the Saskatoon plant. The report provides the framework for a turnkey scale-up project, to provide a highly automated, robustly engineered, continuous production environment with guaranteed performance metrics based on the piloting and testing completed.

The Company is also pleased to note that it continues to make progress on its strategic partnering initiative, and is presently in confidential discussions at various stages with four large multi-national corporations with strong footprints in nutrition and food ingredients businesses. Presently, discussions are oriented towards a direct investment in the Saskatoon plant scale-up and/or additional "greenfield" facilities, to create joint venture structures at the project level. Together with the potential judicious use of debt financing on such projects, the goal is to minimize dilution to shareholders of the public parent Company.

"We are pleased with the depth and breadth of the GEA work, and with the continued success of our efforts to drive scale-up risk down to a practical minimum", said Chris Schnarr, CEO of BioExx. "Our strategic partnering work continues to move forward, and although the pace of late has been challenged somewhat by summer schedules in Europe, we are very pleased with the quality of the corporations we are engaging and we remain committed to a positive outcome. As we have indicated in the past, we are working through this process with an appropriate sense of urgency, but we must exercise a measure of patience to optimize any transaction for our shareholders. Overall, we believe we have delivered very strong confirmation of the key fundamentals of this business, in terms of the efficacy of our technology, the quality of our products, and the strength and health of our markets, which taken together create what we believe is a very solid foundation for the future."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!